Human Immunology ELISA Kits 12
Human TNF- beta (Tumor Necrosis Factor Beta) CLIA Kit (HUES01198)
- SKU:
- HUES01198
- Product Type:
- ELISA Kit
- ELISA Type:
- CLIA Kit
- Size:
- 96 Assays
- Sensitivity:
- 4.69pg/mL
- Range:
- 7.81-500pg/mL
- ELISA Type:
- Sandwich
- Synonyms:
- LT, LTA, TNFB, TNFSF1, TNF Superfamily,Member 1, Lymphotoxin Alpha
- Reactivity:
- Human
- Sample Type:
- Serum, plasma and other biological fluids
Description
Assay type: | Sandwich |
Format: | 96T |
Assay time: | 4.5h |
Reactivity: | Human |
Detection method: | Chemiluminescence |
Detection range: | 7.81-500 pg/mL |
Sensitivity: | 4.69 pg/mL |
Sample volume: | 100µL |
Sample type: | Serum, plasma and other biological fluids |
Repeatability: | CV < 15% |
Specificity: | This kit recognizes Human TNF- beta in samples. No significant cross-reactivity or interference between Human TNF- beta and analogues was observed. |
This kit uses Sandwich-CLIA as the method. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to Human TNF- beta. Standards or samples are added to the appropriate micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human TNF- beta and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human TNF- beta, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured spectrophotometrically by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of Human TNF- beta. The concentration of Human TNF- beta in the samples can be calculated by comparing the RLU of the samples to the standard curve.
UniProt Protein Function: | LTA: Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo. Genetic variations in LTA are a cause of susceptibility psoriatic arthritis (PSORAS). PSORAS is an inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoidlike pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis). Belongs to the tumor necrosis factor family. |
UniProt Protein Details: | Protein type:Cytokine; Apoptosis; Secreted; Secreted, signal peptide Chromosomal Location of Human Ortholog: 6p21. 3 Cellular Component: extracellular space; membrane Molecular Function:cytokine activity; tumor necrosis factor receptor binding; receptor binding Biological Process: response to drug; positive regulation of humoral immune response mediated by circulating immunoglobulin; apoptosis; positive regulation of apoptosis; response to lipopolysaccharide; signal transduction; lymph node development; humoral immune response; defense response to Gram-positive bacterium; positive regulation of interferon-gamma production; cell-cell signaling; negative regulation of fibroblast proliferation; response to hypoxia; positive regulation of chronic inflammatory response to antigenic stimulus; response to nutrient Disease: Psoriatic Arthritis, Susceptibility To; Myocardial Infarction, Susceptibility To; Leprosy, Susceptibility To, 4 |
NCBI Summary: | The encoded protein, a member of the tumor necrosis factor family, is a cytokine produced by lymphocytes. The protein is highly inducible, secreted, and forms heterotrimers with lymphotoxin-beta which anchor lymphotoxin-alpha to the cell surface. This protein also mediates a large variety of inflammatory, immunostimulatory, and antiviral responses, is involved in the formation of secondary lymphoid organs during development and plays a role in apoptosis. Genetic variations in this gene are associated with susceptibility to leprosy type 4, myocardial infarction, non-Hodgkin's lymphoma, and psoriatic arthritis. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Jul 2012] |
UniProt Code: | P01374 |
NCBI GenInfo Identifier: | 135940 |
NCBI Gene ID: | 4049 |
NCBI Accession: | P01374. 2 |
UniProt Secondary Accession: | P01374,Q8N4C3, Q9UKS8, |
UniProt Related Accession: | P01374 |
Molecular Weight: | 22,297 Da |
NCBI Full Name: | Lymphotoxin-alpha |
NCBI Synonym Full Names: | lymphotoxin alpha |
NCBI Official Symbol: | LTA |
NCBI Official Synonym Symbols: | LT; TNFB; TNFSF1 |
NCBI Protein Information: | lymphotoxin-alpha; LT-alpha; TNF-beta; TNF superfamily, member 1; tumor necrosis factor beta; tumor necrosis factor ligand superfamily member 1 |
UniProt Protein Name: | Lymphotoxin-alpha |
UniProt Synonym Protein Names: | TNF-beta; Tumor necrosis factor ligand superfamily member 1 |
Protein Family: | Lymphotoxin |
UniProt Gene Name: | LTA |
UniProt Entry Name: | TNFB_HUMAN |
As the RLU values of the standard curve may vary according to the conditions of the actual assay performance (e. g. operator, pipetting technique, washing technique or temperature effects), the operator should establish a standard curve for each test. Typical standard curve and data is provided below for reference only.
Concentration (pg/mL) | RLU | Average | Corrected |
500 | 50868 52206 | 51537 | 51508 |
250 | 20651 21345 | 20998 | 20969 |
125 | 9850 8942 | 9396 | 9367 |
62.5 | 4414 4610 | 4512 | 4483 |
31.25 | 2475 2123 | 2299 | 2270 |
15.63 | 1333 1167 | 1250 | 1221 |
7.81 | 733 747 | 740 | 711 |
0 | 28 30 | 29 | -- |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, mid range and high level Human TNF- beta were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, mid range and high level Human TNF- beta were tested on 3 different plates, 20 replicates in each plate.
Intra-assay Precision | Inter-assay Precision | |||||
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (pg/mL) | 26.29 | 62.81 | 189.40 | 27.97 | 57.46 | 189.16 |
Standard deviation | 2.74 | 4.89 | 15.99 | 2.61 | 6.03 | 17.93 |
C V (%) | 10.42 | 7.79 | 8.44 | 9.33 | 10.49 | 9.48 |
Recovery
The recovery of Human TNF- beta spiked at three different levels in samples throughout the range of the assay was evaluated in various matrices.
Sample Type | Range (%) | Average Recovery (%) |
Serum (n=5) | 100-113 | 106 |
EDTA plasma (n=5) | 88-98 | 93 |
Cell culture media (n=5) | 92-106 | 98 |
Linearity
Samples were spiked with high concentrations of Human TNF- beta and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.
Serum (n=5) | EDTA plasma (n=5) | Cell culture media (n=5) | ||
1:2 | Range (%) | 96-111 | 84-95 | 92-103 |
Average (%) | 102 | 90 | 97 | |
1:4 | Range (%) | 97-109 | 93-109 | 90-101 |
Average (%) | 102 | 100 | 95 | |
1:8 | Range (%) | 101-116 | 90-106 | 89-103 |
Average (%) | 108 | 97 | 95 | |
1:16 | Range (%) | 95-110 | 84-97 | 101-113 |
Average (%) | 102 | 91 | 108 |
An unopened kit can be stored at 4°C for 1 month. If the kit is not used within 1 month, store the items separately according to the following conditions once the kit is received.
Item | Specifications | Storage |
Micro CLIA Plate(Dismountable) | 8 wells ×12 strips | -20°C, 6 months |
Reference Standard | 2 vials | |
Concentrated Biotinylated Detection Ab (100×) | 1 vial, 120 µL | |
Concentrated HRP Conjugate (100×) | 1 vial, 120 µL | -20°C(shading light), 6 months |
Reference Standard & Sample Diluent | 1 vial, 20 mL | 4°C, 6 months |
Biotinylated Detection Ab Diluent | 1 vial, 14 mL | |
HRP Conjugate Diluent | 1 vial, 14 mL | |
Concentrated Wash Buffer (25×) | 1 vial, 30 mL | |
Substrate Reagent A | 1 vial, 5 mL | 4°C (shading light) |
Substrate Reagent B | 1 vial, 5 mL | 4°C (shading light) |
Plate Sealer | 5 pieces | |
Product Description | 1 copy | |
Certificate of Analysis | 1 copy |
- Set standard, test sample and control (zero) wells on the pre-coated plate and record theirpositions. It is recommended to measure each standard and sample in duplicate. Note: addall solutions to the bottom of the plate wells while avoiding contact with the well walls. Ensuresolutions do not foam when adding to the wells.
- Aliquot 100 µL of standard solutions into the standard wells.
- Add 100 µL of Sample / Standard dilution buffer into the control (zero) well.
- Add 100 µL of properly diluted sample (serum, plasma, tissue homogenates and otherbiological fluids. ) into test sample wells.
- Cover the plate with the sealer provided in the kit and incubate for 90 min at 37 °C.
- Aspirate the liquid from each well, do not wash. Immediately add 100 µL of BiotinylatedDetection Ab working solution to each well. Cover the plate with a plate seal and gently mix. Incubate for 1 hour at 37 °C.
- Aspirate or decant the solution from the plate and add 350 µL of wash buffer to each welland incubate for 1-2 minutes at room temperature. Aspirate the solution from each well andclap the plate on absorbent filter paper to dry. Repeat this process 3 times. Note: a microplatewasher can be used in this step and other wash steps.
- Add 100 µL of HRP Conjugate working solution to each well. Cover with a plate seal andincubate for 30 min at 37 °C.
- Aspirate or decant the solution from each well. Repeat the wash process for five times asconducted in step 7.
- Add 100 µL of Substrate mixture solution to each well. Cover with a new plate seal andincubate for no more than 5 min at 37 °C. Protect the plate from light.
- Determine the RLU value of each well immediately.